ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
Active_not_recruiting
Observational Study
Acute Respiratory Distress Syndrome
Extracorporeal Membrane Oxygenation
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 14 Days – 20
- Sex
- Any
- Study type
- Observational
- Participants needed
- 550 (estimated)
- Sponsor
- University of Michigan · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives.
The first objective is to learn more about children's …
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Time between intubation and ECMO cannulation is less than 240 hours (10 days)
* ECMO support type is respiratory (VV or VA cannulation)
* Chest radiograph with bilateral lung disease
* Moderate or severe pediatric ARDS as measured by oxygenation index or oxygen saturation inde…
Contacts
No contact information available.